Bicycle Therapeutics plc (NASDAQ:BCYC) CTO Michael Skynner Sells 3,287 Shares

Bicycle Therapeutics plc (NASDAQ:BCYC) CTO Michael Skynner sold 3,287 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $46,313.83. Following the transaction, the chief technology officer now directly owns 124,658 shares in the company, valued at approximately $1,756,431.22. This represents a 2.57 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Bicycle Therapeutics Trading Down 0.1 %

Shares of NASDAQ BCYC traded down $0.01 during trading hours on Monday, reaching $14.88. The stock had a trading volume of 289,310 shares, compared to its average volume of 435,603. The business’s fifty day moving average price is $19.27 and its two-hundred day moving average price is $21.86. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -4.52 and a beta of 0.92. Bicycle Therapeutics plc has a 52-week low of $12.17 and a 52-week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.04. The business had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business’s revenue for the quarter was down 50.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.26) EPS. Equities research analysts anticipate that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicycle Therapeutics

Several large investors have recently modified their holdings of the business. Natixis Advisors LLC purchased a new position in Bicycle Therapeutics during the second quarter valued at approximately $261,000. TD Asset Management Inc increased its holdings in shares of Bicycle Therapeutics by 76.7% in the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock valued at $1,967,000 after acquiring an additional 42,200 shares during the period. Renaissance Technologies LLC raised its position in shares of Bicycle Therapeutics by 97.2% in the 2nd quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock worth $6,614,000 after acquiring an additional 161,100 shares in the last quarter. L & S Advisors Inc raised its position in shares of Bicycle Therapeutics by 16.1% in the 2nd quarter. L & S Advisors Inc now owns 58,335 shares of the company’s stock worth $1,181,000 after acquiring an additional 8,075 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth $206,000. Institutional investors own 86.15% of the company’s stock.

Analyst Upgrades and Downgrades

BCYC has been the topic of a number of analyst reports. B. Riley cut their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. HC Wainwright reduced their price objective on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating on the stock in a research report on Monday, December 16th. Needham & Company LLC restated a “buy” rating and set a $38.00 target price on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Stephens started coverage on Bicycle Therapeutics in a research note on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Bicycle Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.